OrPro Therapeutics

OrPro Therapeutics is developing the Theradux® non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus.

Read More

Cystic Fibrosis

In patients with cystic fibrosis, a genetic abnormality causes excessively stiff, viscous mucus that makes simple breathing a challenge and is the underlying cause of impaired lung function and premature death.

Read More

COVID-19

OrPro Therapeutics is developing ORP100S, a novel biologic therapy to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection.

Read More